These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 38377196)
1. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196 [TBL] [Abstract][Full Text] [Related]
3. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers. Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS Hoshiyama H Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617 [TBL] [Abstract][Full Text] [Related]
5. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474 [TBL] [Abstract][Full Text] [Related]
6. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Chen Y; Liu QP; Xie H; Ding J Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578 [TBL] [Abstract][Full Text] [Related]
7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
8. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors. Rathod LS; Dabhade PS; Mokale SN Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967 [TBL] [Abstract][Full Text] [Related]
9. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327 [TBL] [Abstract][Full Text] [Related]
10. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997 [No Abstract] [Full Text] [Related]
12. More to the RAS Story: KRAS Lietman CD; Johnson ML; McCormick F; Lindsay CR Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303 [TBL] [Abstract][Full Text] [Related]
13. Management of Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474 [TBL] [Abstract][Full Text] [Related]
14. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Reck M; Carbone DP; Garassino M; Barlesi F Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836 [TBL] [Abstract][Full Text] [Related]
15. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report. Jiang Y; Liu X; Lv DL; Zhao XL Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588 [TBL] [Abstract][Full Text] [Related]